Fig. 1From: Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinomaFlowchart of patient selection in our observation study. Total of 362 patients with stages IIIB and IV lung adenocarcinoma were enrolled from lung cancer registry database of 1159 patients with non-small cell lung cancer since 2015/01 to 2017/12Back to article page